ACTIVITY OF PEPTIDYL-DIPEPTIDASE A AND LYSINE CARBOXYPEPTIDASE IN RAT SERUM AFTER A SINGLE INJECTION OF REBOXETINE

Kruchinina Anastasya Dmitrievna, Assistant, sub-department of general biology and biochemistry, Penza State University (40 Krasnaya street, Penza, Russia), a.d.kruchinina@mail.ru

577.152.343

Background. The study is aimed at exploring possible changes in peptidyl-dipeptidase A and lysine carboxypeptidase activitу in the serum of rats after a single injection of the reboxetine antidepressant.
Materials and methods. Selective norepinephrine reuptake inhibitor reboxetine is a common treatment for patients with depression. Changes in the activity of peptidyl- dipeptidase A and lysine carboxypeptidase affects the level of regulatory peptides associated with the disease development. The enzyme activitу was determined fotometrically in rat serum after 12, 24, 72 hours since a single injection of reboxetine.
Results. Depression is associated with changes in the level of regulatory peptides in the blood serum. It has been revealed that reboxetine injection effects the activity of peptidyl-dipeptidase A and lysine carboxypeptidase – enzymes regulating the level of biologically active peptides in the blood.
Conclusions. Thus, сhanges in enzyme activity can be one of the mechanisms for regulation of the level of biologically active peptides at the disease correction.

depression, reboxetine, monoamines, regulatory peptides, peptidyldipeptidase A, lysine carboxypeptidase, norepinephrine.

1. Podkorytov V. S., Chayka Yu. Yu. Depressii. Sovremennaya terapiya [Depressions. Modern therapy]. Kharkov: Tornado, 2003, 350 p.
2. Hirschfeld R. M. J Clin Psychiatry. 2000, vol. 61, no. 6, pp. 4–6.
3. Raevskiy K. S. Psikhiatriya i psikhofarmakoterapiya [Psychiatry and psychopharmacotherapy]. 2001, vol. 3, no. 5, pp. 162–166.
4. Schatzberg A. F. J Clin Psychiatry. 2000, vol. 61, no. 10, pp. 31–38.
5. Rotzinger S., Lovejoy D. A., Tan L. A. Peptides. 2010, vol. 31, no. 4, pp. 736–756.
6. Mosolov S. N. Zhurnal nevrologii i psikhiatrii [Journal of neurology and psychiatry]. 2012, vol. 11, no. 2, pp. 29–40.
7. Kormos V., Gaszner B. Neuropeptides. 2013, vol. 47, no. 6, pp. 401–419.
8. Fricker L. D. The AAPS Journal. 2005, vol. 7, no. 2, pp. 449–455.
9. Bao A. M., Swaab D. F. Vitam Horm. 2010, vol. 82, pp. 339–365.
10. Baudin B. Clin Chem Lab Med. 2002, vol. 40, no. 3, pp. 256–265.
11. Matthews K. W., SL Mueller-Ortiz, RA Wetsel. Mol Immunol. 2004, vol. 40, no. 11, pp. 785–793.
12. Naffah-Mazzacoratti M. G., Gouveia T. L. F., Simoes P. S. R., Perosa S. R. World J Biol Chem. 2014, vol. 5, no. 2, pp. 130–140.
13. Taylor W. D., Aizenstein H. J., Alexopoulos G. S. Mol Psychiatry. 2013, vol. 18, no. 9, pp. 963–974.
14. Baghai T. C., Binder E. B., Schule C., Salyakina D., Eser D., Lucae S., Zwanzger P., Haberger C., Zill P., Ising M., Deiml T., Uhr M., Illig T., Wichmann H. E., Modell S., Nothdurfter C., Holsboer F., Müller-Myhsok B., Möller H. J., Rupprecht R., Bondy B. Mol Psychiatry. 2006, vol. 11, no. 11, pp. 1003–1015.
15. Baghai T. C., Schule C., Zwanzger P., Minov C., Zill P., Ella R., Eser D., Oezer S., Bondy B., Rupprecht R. Neurosci Lett. 2002, vol. 328, no. 3, pp. 299–303.
16. de Góis Queiroz A. I., Medeiros C. D., Ribeiro B. M., de Lucena D. F., Macêdo D. S. Med Hypotheses. 2013, vol. 80, no. 3, pp. 259–263.
17. Solov'ev V. B., Gengin M. T. Ukr. bіokhіm. zhurn. [Ukranian biochemical journal]. 2007, vol. 79, no. 6, pp. 106–108.
18. Lowry O. H., Rosebrought N. J., Farr A. G., Randall R. J. J. Biol. Chem. 1951, vol. 193, no. 1, pp. 265–275.
19. Lakin G. F. Biometriya [Biometrics]. Moscow: Vyssh. shk., 1990, 352 p.
20. Maes M. Neuro Endocrinol Lett. 2008, vol. 29, no. 3, pp. 287–291.